Over 100 years ago Western New York gave modern cancer research to the world through what would become the Roswell Park Cancer Institute. Today our region continues to lead the way in medical and scientific research. As a Member of the House Cancer Caucus, Brian has been a steadfast supporter for cancer research, both for local researchers and for the nation’s cancer program generally. Brian has led efforts among his colleagues to increase funding for cancer research and is engaged with the cancer community on innovations that will alleviate suffering due to cancer and ultimately find a cure. Brian has introduced H.R. 1801, the Cancer Drug Coverage Parity Act, which would require health insurance companies to provide the same coverage for new, promising orally-administered anti-cancer medication as it does for traditional intravenous chemotherapy.
More on Cancer Research
Congressman Brian Higgins (NY-26) commends Carl Morrison, MD, DVM, of Roswell Park Cancer Institute (RPCI) on his appointment to the federal Advisory Panel on Clinical Diagnostic Laboratory Tests. The new 15-member panel has been established by the Centers for Medicare & Medicaid Services (CMS), a division of the U.S. Department of Health and Human Services, to help guide and inform CMS leadership on decisions and policies regarding new diagnostic laboratory tests.
Congressman Brian Higgins (NY-26) spoke on the Floor of the House of Representatives today regarding H.R. 2739, the Cancer Drug Coverage Parity Act. The bipartisan legislation would require health insurance companies to provide equal coverage for traditional, intravenous chemotherapy and orally-administered prescription chemotherapy drugs.
Congressman Brian Higgins (NY-26) announces the formation of the National Institutes of Health (NIH) Caucus, dedicated to increasing NIH funding and support for biomedical research. Higgins co-chairs the NIH Caucus with Representatives Rosa DeLauro (CT-3) and Peter King (NY-2).
Congressman Brian Higgins (NY-26) announced that Roswell Park Cancer Institute (RPCI) researchers Brahm Segal, MD, and Kirsten Moysich, PhD, have received a five-year, roughly $3 million award from the National Cancer Institute (NCI) to study immune responses in women with ovarian cancer and to identify biomarkers that can predict response to treatment. First-year funding will be $589,735, and funding in each of the subsequent four years of the project is expected to be at a similar level.
For-Robin, a University at Buffalo spinoff company, has received a $2 million grant from the National Cancer Institute (NCI) to study and develop a promising potential treatment for breast and other types of cancer, UB and U.S. Congressman Brian Higgins have announced.
For-Robin was founded in 2012 by Kate Rittenhouse-Olson, PhD, a professor of biotechnical and clinical laboratory sciences, and microbiology and immunology at UB.
Congressman Brian Higgins (NY-26) announced that Roswell Park Cancer Institute (RPCI) researcher Xuefang Cao, MD, PhD, has received a five-year, $2.01 million award from the National Cancer Institute (NCI) to develop better therapies for blood cancers.
“This award once again represents the confidence the National Cancer Institute has in Roswell Park Cancer Institute and role of Roswell Park’s researchers in identifying the next best treatments in cancer,” said Congressman Higgins.
Washington, D.C. - U.S. Senator Kirsten Gillibrand and Congressman Brian Higgins today announced a Roswell Park Cancer Institute (RPCI) researcher has received a five-year, $2.01 million grant from the National Cancer Institute (NCI) to explore the paradoxical observation of how normal cells of the body influence the progression of breast cancer.
Congressman Brian Higgins (NY-26) recognized February 4, 2015 as World Cancer Day by announcing the introduction of legislation aimed at the fight to rid the world of cancer and other debilitating diseases.
Congressman Brian Higgins (NY-26) announced today the House of Representatives approval of H.R. 5185, the Breast Health Education and Awareness Requires Learning Young (EARLY) Act Reauthorization. This legislation reauthorizes the EARLY Act, originally signed into law in 2010, through fiscal year 2019.
Congressman Brian Higgins (NY-26) recently spoke on the House floor in support of increased funding for medical research. Adjusting for inflation, the National Institutes of Health (NIH) receive nearly 25 percent less funding today than it did in 2003. This is why Congressman Higgins recently joined Congresswoman DeLauro to introduce H.R. 5580, the Accelerating Biomedical Research Act. This legislation will incrementally increase funding for the National Institutes of Health (NIH) over the next seven years.